European rating of drug harms
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: The present paper describes the results of a rating study performed by a group of European Union (EU) drug experts using the multi-criteria decision analysis model for evaluating drug harms. Methods: Forty drug experts from throughout the EU scored 20 drugs on 16 harm criteria. The expert group also assessed criteria weights that would apply, on average, across the EU. Weighted averages of the scores provided a single, overall weighted harm score (range: 0–100) for each drug. Results: Alcohol, heroin and crack emerged as the most harmful drugs (overall weighted harm score 72, 55 and 50, respectively). The remaining drugs had an overall weighted harm score of 38 or less, making them much less harmful than alcohol. The overall weighted harm scores of the EU experts correlated well with those previously given by the UK panel. Conclusion: The outcome of this study shows that the previous national rankings based on the relative harms of different drugs are endorsed throughout the EU. The results indicates that EU and national drug policy measures should focus on drugs with the highest overall harm, including alcohol and tobacco, whereas drugs such as cannabis and ecstasy should be given lower priority including a lower legal classification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Self-citationDevelopment of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“Though it is advocated to provide the assessors with fact sheets about the 20 drugs as sound and defensible inputs for the scores as done in the Dutch ranking procedure, the Dutch ranking proved to be very comparable to the present and previous (Nutt et al., 2007, 2010) rankings.”
ResultSelf-citationRanking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010) · European Addiction Research · doi:10.1159/000317249 · Cited by 191 · cited 1×
“Of the 40 experts, two British experts had previously participated in the May 2010 decision conference of the Independent Scientific Committee on Drugs (ISCD) (Nutt et al., 2010) and one expert who participated in the Dutch ranking study (van Amsterdam et al., 2010).”
BackgroundPhillips, L. D. (2007) · Advances in Decision Analysis · doi:10.1017/cbo9780511611308.020 · Cited by 169
Self-citationCaulkins, J. P., Reuter, P., & Coulson, C. E. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03461.x · Cited by 79
The high harm score of alcohol. Time for drug policy to be revisited?
van Amsterdam, J., & van den Brink, W. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112472559 · Cited by 29
Cited by
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“…have consistently rated psilocybin as the least harmful and potentially ‘most beneficial’ drug of potential misuse (Carhart-Harris and Nutt 2013; van Amsterdam et al. 2015)—although the influence of context (e.g. expectations and environmental factors) on potential harms and benefits has been…”
BackgroundSelf-citationSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Self-citationThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
“…alarmist campaigning that so negatively affected perceptions of psychedelics after the 1960s, subjective (Carhart-Harris and Nutt, 2010, 2013; van Amsterdam et al, 2015), naturalistic/ observational (Bouso et al, 2012), and population-based data (Hendricks et al, 2015) indicate a positive…”
BackgroundPublic health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Metadata
- Authors
- van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W.
- Affiliations
- Department of Psychiatry, University of Amsterdam, Amsterdam, the Netherlands
- Imperial College London (GB)
- London School of Economics and Political Science (GB)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-06
- Volume
- 29
- Issue
- 6
- Pages
- 655-660
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2015666695
- Cited by
- 229
- References
- 7
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 22 · 2023: 44 · 2022: 26 · 2021: 22 · 2020: 22 · 2019: 14 · 2018: 16 · 2017: 21 · 2016: 10 · 2015: 3
- FWCI
- 13.01
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Commission
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Law › Criminal Law and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- multi-criteria decision making, expert panel, alcohol, heroin, crack cocaine, cannabis, ecstasy, drug policy, drug classification
- MeSH terms
- Ethanol, Cannabis, European Union, Humans, Illicit Drugs, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European rating of drug harms. https://app.cochat.ai/papers/10.1177/0269881115581980
- The paper
- van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015). European rating of drug harms. Journal of Psychopharmacology. https://doi.org/10.1177/0269881115581980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.